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Brahma-related gene 1 (Brg1) is a key gene in inducing the expression of important endogenous antioxidant enzymes, including
heme oxygenase-1 (HO-1) which is central to cardioprotection, while cardiac HO-1 expression is reduced in diabetes. It is unknown
whether or not cardiac Brg1 expression is reduced in diabetes. We hypothesize that cardiac Brg1 expression is reduced in diabetes
which can be restored by antioxidant treatment with N-acetylcysteine (NAC). Control (C) and streptozotocin-induced diabetic (D)
rats were treated with NAC in drinking water or placebo for 4 weeks. Plasma and cardiac free15-F2t-isoprostane in diabetic rats
were increased, accompanied with increased plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6),
while cardiac Brg1, p-STAT3 and HO-1 protein expression levels were significantly decreased. Left ventricle weight/body weight
ratio was higher, while the peak velocities of early (E) and late (A) flow ratio was lower in diabetic than in C rats. NAC normalized
tissue and plasma levels of 15-F2t-isoprostane, significantly increased cardiac Brg1, HO-1 and p-STAT3 protein expression levels
and reduced TNF-alpha and IL-6, resulting in improved cardiac function. In conclusion, myocardial Brg1 is reduced in diabetes
and enhancement of cardiac Brg1 expression may represent a novel mechanism whereby NAC confers cardioprotection.
1. Introduction
Diabetes mellitus-induced cardiovascular complication is a
growing life-threatening disease worldwide. Diabetic car-
diomyopathy (DCM) is a diabetes-associated ventricular
dysfunction, resulted from abnormal ventricular structural
alteration that is independent of other etiological factors such
as hypertension [1]. Studies have shown that hyperglycemia-
induced oxidative stress and the subsequent inflammation
play critical roles in the development and progression
of diabetic cardiomyopathy [2, 3]. Hyperglycemia-induced
oxidative stress mainly results from increased production of
reactive oxygen species (ROS) with or without concomitantly
damped antioxidant defense system [4, 5]. Our previous
study found that the major endogenous antioxidant enzyme
superoxide dismutase (SOD), which plays an important
role in balancing ROS generation and the overall tissue
antioxidant capacity, was increased in both the plasma and
heart tissue of rats at a relatively early stage (4 weeks)
of diabetes, but tissue and plasma levels of free 15-F
2t-
isoprostane, a specific marker of lipid peroxidation, were also
increased [6]. This indicates that the upregulation of SOD
is not sufficient to resist hyperglycemia-induced oxidative
stress. Of note, another important enzyme, heme oxygenase-1
(HO-1), a stress-inducible cytoprotective defense enzyme, has
been shown to exert cytoprotective effect against oxidative
insults [7]. Also, studies showed that enhancing myocardial
HO-1 expression could attenuate diabetes-induced cardiac
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dysfunction. However, in contrast to the compensatory
increase of SOD during early diabetes mellitus, a number
of studies showed that myocardial HO-1 expression was
significantly decreased in the myocardium of diabetic rats
[8, 9].Thus, unveiling the underlying mechanisms governing
the reduction of myocardial HO-1 in diabetes should lead
to the development of novel therapies to upregulate HO-1
expression in diabetic heart.
It has been reported that, in response to oxidative
stress, Brahma-related gene 1 (Brg1) is necessarily required
in Nuclear factor-E2 related factor 2 (Nrf2)/ARE-mediated
induction of HO-1 [10]. Brg1 is the core ATPases in the
SWI/SNF complex, which plays a central role in the activation
and transcription of genes in mammalian cells [11]. The
deficiency of Brg1 results in the dissolution of discrete
heterochromatin domains, aberrant mitotic progression, and
genomic instability, which eventually induces cell death or
cell apoptosis [12]. A recent study showed that Brg1 can
bind to the promoters of antioxidant defense genes and
protect cells from oxidative damage [13], which means that
Brg1 can exert antioxidative effect. Furthermore, increasing
evidence shows that Brg1 can regulate gene expression during
cardiac growth, differentiation, and hypertrophy [14–16].
Brg1 null mice embryos die when cardiomyocytes expansion
and maturation begin, while in adult cardiomyocytes, Brg1
is activated by cardiac stresses and assembles a chromatin
complex to activate downstream signal transduction, includ-
ing HO-1 and signal transducer and activator of transcription
3 (STAT3) [10, 16–18], which are protective against ROS-
induced cardiomyopathy. Studies by us and others found
that myocardial HO-1 expression is reduced in diabetic rats
[8, 9] which is accompanied with reduced phosphorylation
of STAT3 (p-STAT3, the activated status of STAT3) [19]. We
postulated that reductions in myocardial HO-1 and STAT3 in
diabetes may be a consequence of reduction in cardiac Brg1
expression subsequent to hyperglycemia-induced oxidative
stress.
Accumulated evidence proves that therapies that can
reduce oxidative stress are effective to attenuate the devel-
opment of diabetic cardiomyopathy [20, 21]. Our previous
study also found that treatment with the antioxidant N-
acetylcysteine (NAC) could attenuate the increase in inflam-
mation factors tumor necrosis factor-alpha (TNF-alpha) and
interleukin 6 (IL-6) [6] and ameliorate myocardial dysfunc-
tion [2] in diabetic rats. Moderate levels of TNF-alpha or
IL-6 have been shown to initiate the activation of STAT3,
a key protein in cardioprotective signaling pathway, whose
activation is Brg1 dependent [22, 23]. Therefore, the current
study was designed to test the hypothesis that myocardial
Brg1 is reduced in diabetes and antioxidant NAC may
enhance cardiac Brg1 expression and concomitantly increase
cardiac STAT3 activation and confer cardioprotection in
diabetes.
2. Materials and Methods
2.1. Animals and Introduction of Diabetes. Sprague-Dawley
male rats (220 ± 20 g, 8 weeks of age) were obtained from
the Laboratory Animal Service Center (University of Hong
Kong). All rats were allowed to adapt in their houses and
have free access to standard chow and water according to
the principles of Animal Care of the University of Hong
Kong. The experiment procedures were approved by the
Committee on the Use of Live Animals in Teaching and
Research (CULATR). Diabetes was induced by a single tail
vein injection of streptozotocin (STZ) at the dose of 65mg/kg
body weight (Sigma-Aldrich, St. Louis, MO), freshly dis-
solved in 0.1M citrate buffer (PH 4.5) under anesthesia with
sodium pentobarbital (65mg/kg body weight), while control
rats were given equal volume of citrate buffer alone. After
three days of injection, blood glucose was measured using a
Glucose Analyzer (Bayer Healthcare, Bayer AG, Germany),
and rats with blood glucose over 16.7mM were considered
diabetic.
2.2. Experimental Protocol. Rats were randomly divided into
three groups (𝑛 = 6 per group): control (C); diabetes (D);
diabetes treated with NAC (1.5 g/kg/day) (D + NAC). NAC
was administered to theD+NACgroupdissolved in drinking
water for 4weeks after induction of diabetes starting oneweek
after the onset of diabetes. Upon completion of treatment, the
rats were anticoagulated with heparin (1000 IU/kg) and then
anaesthetized with pentobarbital sodium (65mg/kg body
weight). Blood samples were obtained from the inferior vena
cava, and plasma was separated and stored at −80∘C for
further analysis. Rats were sacrificed after completion of
echocardiographic assessment of cardiac function, and hearts
were harvested and rinsed with ice-cold phosphate buffer
saline, dried, and weighted.
2.3. Echocardiography. At the end of 4-week treatment, the
rats were examined by echocardiography using a High Reso-
lution Imaging System (Vevo 770, VisualSonics Inc., Canada)
equipped with a 17.5-MHz liner array transducer. The follow-
ing validated parameters were automatically calculated by the
ultrasound machine: LV end-diastolic volumes (LVVd), LV
end-systolic volume (LVVs), fractional shortening (FS), ejec-
tion fraction (EF), and stroke volume (SV). M-mode images
were recorded to detect heart rate (HR), LV internal diameter
in systole (LVIDs) and diastole (LVIDd), interventricular
septal thickness in systole (IVSs) and in diastole (IVSd), and
LV posterior wall thickness in systole (LVPWs) and diastole
(LVPWd). LV mass was assessed by calculating the formula:
LV mass = 1.053 [(LVIDd + LVPWd + IVSd)3− LVIDd3] ×
0.8. The peak velocities of early (E) and late (A) flows were
obtained from the apical four-chamber view. The E/A ratio
and the isovolumetric relaxation time (IVRT) were used as
indices of LV diastolic function.
All recordings were performed in rats that underwent
inhalation of 3% isopentane in air throughout the whole pro-
cess, and echocardiography was conducted by investigators
who were blinded to the experimental group as we reported
[24].
2.4. Measurement of Free 15-F
2t-Isoprostane, TNF-Alpha,
and IL-6. Free 15-F
2t-isoprostane (15-F2t-IsoP), a specific
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marker of oxidative stress, was measured by using an
enzyme-linked immunoassay kit (Cayman chemical, Ann
Arbor, MI) as described [20]. Plasma samples and homog-
enized heart tissue (in PBS) were purified using Affin-
ity Sorbent and Affinity Column (Cayman chemical, Ann
Arbor, MI), then processed for analysis, according to
the protocol provided by the manufacturer. The values
of plasma or cardiac free 15-F
2t-IsoP were expressed as
pg/mL in plasma or pg/mg protein in cardiac homogenates,
respectively.
Plasma levels of TNF-alpha and IL-6 were determined by
using the commercially available rat ELISA kit (Bender Med,
Vienna, Austria).
2.5. Western Blot Assay for HO-1, STAT3, and p-STAT3.
Frozen heart tissue was homogenized using lysis buffer
(20mmol/L Tris-HCl PH = 7.5, 50mmol/L 2-mercaptoeth-
anol, 5mmol/L EGTA, 2mmol/L EDTA, 1% NP40, 0.1%
sodium dodecyl sulfonate (SDS), 0.5% deoxycholic acid,
10mmol/L NaF, 1mmol/L PMSF, 25mg/mL leupeptin, and
2mg/mL aprotinin) for 30min and then sonicated and
centrifuged at 12000 g for 20min at 4∘C. Protein concentra-
tions were determined using the Bradford assay (Bio-Rad,
USA). Samples containing equal amounts were separated
on a 10% SDS-polyacrylamide gel, and then proteins were
transferred to PVDF membrane overnight at 4∘C. Mem-
branes were blocked with 5% nonfat milk in Tris-Buffered
Saline (TBS)-Tween for 1 hour and were incubated with anti-
Brg1 (Abcam, USA) or anti-STAT3, anti-phospho-STAT3
(T705), anti-HO-1 antibodies (Cell Signaling Technology,
Beverly,MA,USA), andGAPDH (Cell Signaling Technology,
Beverly, MA, USA) at 1 : 1000 dilution for overnight at
4∘C. After washing with phosphate buffered saline-tween
(PBST) three times for 30min, membranes were then incu-
bated with horseradish-peroxidase- (HRP-) conjugated anti-
rabbit IgG at 1 : 2000 dilution for 1 hour. Protein bands
were developed with enzymatic chemiluminescence, and
images were measured by a densitometer with analysis
software.
2.6. Statistical Analysis. Data are presented as means ±
standard error of the mean (S.E.M.). Data were analysed by
the ANOVA within the same group and between groups.
Multiple comparisons of group means were analyzed by
Tukey’s test. The analysis was performed using statistical
software package (GraphPad Prism, San Diego, CA, USA).
Significant difference was defined as 𝑃 ≤ 0.05.
3. Results
3.1. General Characteristics and Effects of NAC Treatment.
Administration of STZ resulted in increased plasma glucose
and food and fluid intake and reduced body weight gain
as compared with age-matched control rats (all 𝑃 < 0.05,
Table 1). Treatment with NAC for 4 weeks significantly
reduced food consumption and water intake in diabetic rats
(𝑃 < 0.05, D + NAC versus D) but did not have significant
effect on glucose levels and body weight gain.
Table 1: General Characteristics of Rats at the End of the Study.
C D D + NAC
Water intake (mL/kg/day) 121.1 ± 8.3 840.3 ± 10.7∗ 421.1 ± 7.1∗
Food intake (g/kg/day) 66.0 ± 1.3 195.1 ± 3.8∗ 145.5 ± 3.5∗
Body weight (g) 486.3 ± 12.7 310.9 ± 17.2∗ 304.5 ± 12.5∗
Plasma glucose (mM) 6.2 ± 0.8 27.7 ± 1.7∗ 26.1 ± 1.5∗
All values are expressed as Mean ± S.E.M. 𝑛 = 6 per group. Control
(C) or STZ-induced diabetic rats with untreated (D) or treated with NAC
(1.5 g/kg/day) for 4 weeks. ∗𝑃 < 0.05 versus C; #𝑃 < 0.05 versus D.
Table 2: Effects of NAC treatment on the level of free 15-F2t-
isoprostane in plasma and heart tissue.
C D D + NAC
Plasma
(pg/mL) 125.1 ± 18.9 245.0 ± 19.1
∗∗
150.7 ± 21.4
#
Heart tissue
(pg/mg protein) 101.3 ± 17.3 208.5 ± 20.6
∗
167.2 ± 18.5
#
All values are expressed as Mean ± S.E.M. 𝑛 = 6 per group. Control
(C) or STZ-induced diabetic rats with untreated (D) or treated with NAC
(1.5 g/kg/day) for 4 weeks. ∗𝑃 < 0.05 versus C; #𝑃 < 0.05 versus D.
3.2. Oxidative Stress Marker Free 15-F
2t-IsoP Levels. Com-
pared with the control group, the levels of free 15-F
2t-IsoP
were significantly increased in both the plasma and cardiac
tissues of diabetic rats (𝑃 < 0.01 or 𝑃 < 0.05 versus C,
Table 2). NAC treatment reduced plasma and cardiac tissue
15-F
2t-IsoP to a level comparable to that in the control (𝑃 <
0.05 versus D, 𝑃 > 0.05 D + NAC versus C, Table 2).
3.3. Effect of NACon LeftVentricularDimension and Function.
As shown in Table 3, LVM was much lower in diabetic rats
(𝑃 < 0.05 versus C), despite the fact that there were no signif-
icant differences in IVSd, IVSs, LVIDs, LVPWd, and LVPWs
between the control and the diabetic rats. However, LVM to
body weight ratio, an indicator of myocardial hypertrophy,
was remarkably increased in diabetic rats (𝑃 < 0.05 versus C).
NAC reduced LVM to bodyweight ratio to a level comparable
to that in the control (𝑃 < 0.05, D + NAC versus D; 𝑃 > 0.05
D + NAC versus C, Table 3). The HRs of diabetic rats were
significantly decreased as compared to those of the controls
(𝑃 < 0.05 versus C Table 3). NAC had no effect on HR.
LVVd and the E/A ratio in diabetic rats were significantly
decreased, while IVRT increased (all 𝑃 < 0.01 versus C
Table 3). This is indicative of compromised LV relaxation,
which may contribute to the significantly reduced SV (𝑃 <
0.05D versus C, Table 3). NAC treatment did not have signif-
icant effects on LVVd and IVRT nor did it improve SV (𝑃 >
0.05 D + NAC versus D, Table 3) but remarkably increased
E/A ratio which primarily resulted from a reduction in MVA
(𝑃 < 0.05 D + NAC versus D, Table 3). There was no
difference in values of FS and EF between the control and
diabetic rats.
3.4. Plasma Il-6 and TNF-𝛼. As shown in Figures 1(a) and
1(b), the plasma levels of TNF-𝛼 and IL-6 in diabetic rats were
significantly increased as compared with the control group
4 Journal of Diabetes Research
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Figure 1: Effects of N-acetylcysteine (NAC) treatment on the level of TNF-alpha (a) and IL-6 (b) in plasma. Control (C) or STZ-induced
diabetic rats without treatment (D) or with NAC treatment (1.5 g/kg/day, D + NAC) for 4 weeks. All values are expressed as mean ± S.E.M.
𝑛 = 6 per group. ∗𝑃 < 0.05 versus C; #𝑃 < 0.05 versus D.
Table 3: M-mode Echocardiographic and transmitral Doppler flow
velocity indices of LV dimensions and functions.
C D NAC
LVIDd (mm) 8.30 ± 0.17 7.90 ± 0.15 7.75 ± 0.15∗
LVIDs (mm) 4.80 ± 0.14 4.55 ± 0.13 4.65 ± 0.25
IVSs (mm) 2.25 ± 0.11 2.24 ± 0.08 2.08 ± 0.06
IVSd (mm) 1.72 ± 0.06 1.78 ± 0.05 1.60 ± 0.05
LVPWs (mm) 3.06 ± 0.07 2.92 ± 0.05 2.57 ± 0.05∗
LVPWd (mm) 1.92 ± 0.04 1.87 ± 0.05 1.62 ± 0.03#
LVM (mg) 964 ± 27.5 812 ± 14.3∗ 707 ± 18.7∗
LVM/body 1.90 ± 0.04 2.44 ± 0.07∗ 2.17 ± 0.04#
weight (mg/g)
HR (bpm) 323 ± 7.8 285 ± 10.8∗ 286 ± 9.2∗
LVVd (𝜇L) 372.7 ± 23.4 318.5 ± 24.2∗ 319.7 ± 18.4
LVVs (𝜇L) 107.8 ± 10.6 93.7 ± 9.8 101.5 ± 13.2
IVRT (ms) 21.6 ± 1.6 32.5 ± 1.8∗ 28.5 ± 1.4∗
MV E (cm/s) 133.2 ± 58.3 1217 ± 30.2 1181.7 ± 62.2
MV A (cm/s) 909.5 ± 36.2 1028.9 ± 36.1 838.6 ± 63.8#
E/A 1.49 ± 0.09 1.19 ± 0.03∗ 1.45 ± 0.07#
SV (𝜇L) 277.8 ± 17.8 226.7 ± 17.4∗ 218.3 ± 12.2∗
FS (%) 42.5 ± 0.9 42.1 ± 0.8 40.7 ± 1.0
EF (%) 71.6 ± 1.7 72.2 ± 1.7 68.8 ± 3.0
All values are expressed as Mean ± S.E.M. 𝑛 = 6 per group. M-mode
Echocardiographic and transmitral Doppler flow velocity indices of LV
dimensions and functions in Control (C), Diabeties (D), Ruboxistaurin
(RBX), N-acetylcysteine (NAC) rats. ∗𝑃 < 0.05 or 0.01 versus C; #𝑃 <
0.05 or 0.01 versus D. LVIDd: LV internal diastolic diameter; LVIDs: LV
internal systolic diameter; IVSs: systolic interventricularseptal thickness;
IVSd: diastolic interventricularseptal thickness; LVPWs: LV systolic pos-
terior wall thickness; LVPWd: LV diastolic posterior wall thickness; LVM:
LV mass; HR: heart rate; LVVd: LV end-diastolic volume; LVVs: LV end-
systolic volume; IVRT: isovolumetric relaxation time; SV: stroke volume; FS:
fractional shortening; EF: ejection fraction.
(𝑃 < 0.05). NAC treatment reduced plasma TNF-𝛼 and IL-6
to a level comparable to that in the control (𝑃 < 0.05 versus
D; 𝑃 > 0.05 versus C) although they were slightly higher than
that in the control rats.
3.5. Effect of NAC on Protein Expression of Brg1. To investigate
whether the cardiac protein expression of Brg1 is altered in
diabetic rats at an early stage of the disease and whether or
not it can be affected by antioxidants, we explored the effects
of NAC on cardiac levels of Brg1 in STZ-induced diabetic
rats 4 weeks after the establishment of diabetes. As shown in
Figure 2(a), the protein expression of Brg1 was significantly
decreased in diabetic rats as compared to that of control
group (𝑃 < 0.01). NAC treatment partially but significantly
restored the protein expression of Brg1.
3.6. Effect of NAC on Protein Expression of STAT3 and HO-1.
Recent study demonstrated that Brg1 is required to establish
chromatin accessibility at STAT3 binding targets [18], which
is essential to enable these sites to respond to downstream
signaling. Therefore, in addition to exploring the changes
of myocardial Brg1 protein in diabetes, we also investigated
themyocardial protein levels and phosphorylation/activation
status of STAT3 in diabetic heart. As shown in Figures 2(c)
and 2(d), the protein expression of p-STAT3 (Tyr705 and
Ser727) but not total STAT3 was significantly reduced in the
myocardium of diabetic rats, accompanied with concomitant
reduction of cardiac protein expression of HO-1 (all 𝑃 <
0.05 versus C, Figure 2(b)), an important signaling protein
downstream of Brg1. NAC completely restored myocardial
p-STAT3 at site Tyr705 and HO-1 protein expression and
partially but significantly enhanced p-STAT3 at site Ser-727
in diabetic rats (𝑃 < 0.01 versus D; 𝑃 < 0.05, 𝑃 < 0.01 versus
C).
4. Discussion
Consistent with our previous studies, we have shown in the
current study that oxidative stress increased in the early
stage (at 4 weeks) rats with STZ-induced type 1 diabetes
Journal of Diabetes Research 5
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Figure 2: Effects of N-acetylcysteine (NAC) treatment on the protein expression of Brg1 (a), HO-1 (b), and p-STAT3 ((c), (d)) inmyocardium.
Control (C) or STZ-induced diabetic rats without treatment (D) or with NAC treatment (1.5 g/kg/day, D + NAC) for 4 weeks. All values are
expressed as mean ± S.E.M. 𝑛 = 6 per group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus C; #𝑃 < 0.05, ##𝑃 < 0.01 versus D.
as indicated by a significant increase in both plasma and
heart tissue levels of free 15-F
2t-isoprostane, a specific index
of oxidative stress [25]. Enhanced levels of oxidative stress
were accompanied by increased TNF-alpha and IL-6. In the
current study, we further discovered that diabetic rat hearts
exhibited decreased expression of Brg1, which was coincident
with decreased cardiac expressions of p-STAT3 and HO-1
and compromised cardiac diastolic function as assessed by
echocardiography. Effective antioxidant treatment with NAC
evidenced as complete prevention of hyperglycemia-induced
increases in plasma and heart tissue free 15-F
2t-isoprostane
significantly attenuated the reduction ofmyocardial Brg1 pro-
tein expression, subsequently significantly enhancedmyocar-
dial p-STAT3 and HO-1, and improved cardiac relaxation
in diabetic rats. To our knowledge, this is the first study
to explore the changes of cardiac Brg1 in diabetic rats and
the effectiveness of antioxidant treatment on Brg-1 cardiac
expression in diabetes.
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Oxidative stress occurs in diabetes as a consequence
of hyperglycemia-induced abnormalities, including glucose
autooxidation, the formation of advanced glycation end
products, and impairment of antioxidant defense system [4].
We previously reported that the heart tissue SOD activity
was compensatorily increased, but both the plasma and heart
tissue levels of free 15-F
2t-isoprostanes were still increased in
diabetic rats at the early stage of 4-week diabetes [6], which
indicates that, during early stage of diabetes, compensatory
increase in myocardial SOD was not sufficient to combat
hyperglycemia-induced oxidative stress.While in our current
study conducted in the same model of early stage of 4-week
diabetes [6], we showed that the protein expression of HO-
1, another important antioxidative enzyme, was decreased
significantly in the myocardium of diabetic rats, which
suggests that a decrease in HO-1 expression may be a major
contributor to hyperglycemia-induced oxidative stress in
early diabetes. Many studies confirmed that HO-1 plays a
central role in cardiovascular protection [26]. It has been
shown that, in response to oxidative stress, HO-1 expression
can be induced through the Nrf2/ARE signaling pathway,
while, effectiveNrf2/ARE signaling needs the participation of
Brg1 [10]. However, as we showed in the current study, cardiac
Brg1 expression in rats at the 4th week after STZ-induced
type 1 diabetes was significantly reduced, which might be
the major reason why cardiac protein expression of HO-
1 was significantly decreased. Antioxidant NAC normalized
cardiac free 15-F
2t-isoprostanes in diabetic rats and enhanced
myocardium Brg1 expression, leading to full restoration of
cardiac HO-1 expression. This finding suggests that enhanc-
ing Brg1 may represent a novel mechanism whereby NAC
confers its antioxidant protection at least in early diabetes.
Consistentwith our recent study findings [24], we showed
in the current study that ventricular dysfunction occurs dur-
ing early stage of diabetes manifested as abnormal relaxation
function that was coincident with significant reduction in
myocardial Brg1 protein expression. This finding is similar
in nature to a previous study which showed that mice with
cardiac-specific deletion of Brg1 developed impaired cardiac
relaxation evidenced as reduction in E/A ratio as determined
by ultrasound [15]. The findings by us and others [15] point
out the importance of Brg1 in the maintenance of normal
cardiac function. In our study, NAC treatment mediated
improvement in cardiac diastolic function manifested as
significant elevation of E/A ratio in diabetes which may
be contributable to enhancement of cardiac Brg1 protein
expression.
The risk of progression to heart failure after myocardial
ischemia and reperfusion was significantly higher in dia-
betes compared with nondiabetes [27]. Myocardial STAT3
is an important transcription factor in the SAFE path-
way (i.e., JAK2/STAT3 signaling cascade), especially during
myocardium ischemia reperfusion injury [28], but cardiac p-
STAT3 is reduced in diabetes [19]. Further, STAT3-deficient
mice spontaneously develop a form of dilated cardiomy-
opathy similar to that which occurred in diabetic mice
[29], indicating that reduced STAT3 activation may lead
to myocardial remodeling. Brg1 is necessarily required to
establish chromatin restructure for the activation of STAT3,
High glucose
ROS
Brg1
Cardiac hypertrophy Cardiac dysfunction
NAC
HO-1 p-STAT3
Figure 3: Schematic diagram proposing that Enhancement of
cardiac Brg1 expression represents a novel mechanism whereby
antioxidant N-acetylcysteine (NAC) enhanced cardiac HO-1 and p-
STAT3 expression, and attenuated cardiac diastolic dysfunction in
diabetes.
especially STAT3 phosphorylation at site Try705 in various
cells such as cancer cell and macrophagocyte [30], and
for STAT3 signaling transduction. In the current study, we
also found that STAT3 phosphorylation at both Ser727 and
Try705 was dramatically reduced in the hearts of diabetic
rats, which was concomitant with decreased Brg1 expression.
NAC treatment increased the expression of Brg1 and conse-
quently enhanced p-STAT3 at both Try705 and Ser727 in the
myocardium of diabetic rats. Based on the fact that Brg1 is
a needed component for STAT3 activation [30], our findings
suggest that Brg1 may play a key role in the transcriptional
induction of cardiac STAT3, especially at Try705 in diabetic
rats. NACmay have increased STAT3 phosphorylation in dia-
betes through enhancing Brg1 expression, although further
study is needed to confirm this hypothesis.
Inflammation has been considered as an important pro-
cess in the progression of diabetes [31, 32]. Elevation of TNF-
alpha and IL-6 was detected in diabetes, which was related to
the progression of diabetic complications [33]. In the current
study, we showed that plasma levels of TNF-alpha and IL-
6 were remarkably elevated in diabetic rats at 4 weeks after
the establishment of diabetes, and NAC treatment decreased
them, indicating that NAC can inhibit the inflammation
reaction in diabetes. Studies found that moderate levels
of TNF-alpha or IL-6 can increase the phosphorylation of
STAT3 at Try705, and this is Brg1 dependent [22, 23]. In
our study, we found that the levels of TNF-alpha and IL-6
in NAC-treated diabetic rats were significantly lower than
that in the untreated diabetes, but still slightly higher than
that in nondiabetic rats. These remaining slight elevations
in TNF-alpha and IL-6 after NAC treatment should have
contributed to the enhancement of cardiac p-STAT3 as seems
Journal of Diabetes Research 7
to be in the NAC treated group, which added to the effect of
Brg1 in enhancing cardiac Brg1-mediated STAT3 activation
as previously mentioned. This explains why NAC treatment
did not completely restore cardiac Brg1 protein expression in
diabetic rats but completely restored cardiac p-STAT3 at site
Try705.
In summary, we first report that the expression of Brg1
was decreased significantly in the myocardium of diabetic
rats, which may be responsible at least in part for the reduced
expressions of HO-1 and p-STAT3 and impairment of cardiac
diastolic function as summarized in the schematic diagram
(Figure 3). Enhancement of cardiac Brg1 expressionmay thus
represent a novel mechanism whereby NAC enhanced car-
diac HO-1 and p-STAT3 expressions and attenuated cardiac
diastolic dysfunction in diabetes.
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